ISBSS Seminar Series: Steve Elliott, Ph.D. - Amgen Consultant
Monday, November 18, 2013 from 12:00 PM to 1:00 PM (PST)
Industrial Strength Bio Seminar Series
Monday, November 18, 2013
Seminar 12 Noon – 1:00 P.M. ~ 517 Bldg. – Lecture Hall
"How Dare they Dope with our Medicines:
The Epo Story”
- The purpose of medicines is to treat patients who need them.
- Doping is the illicit use of drugs or blood products to enhance athletic performance.
- Some athletes will experiment with any new drug that has the potential to enhance performance, and doping has occurred in virtually all sports.
- Doping is unethical, unfair and there is no medically justified reason to expose a healthy person to such unnecessary risks.
Steve Elliot, PhD
Dr. Elliott joined Amgen in 1983 as a research scientist. During his early years at the company, he performed structure-function studies on erythropoietin and the erythropoietin receptor. This work led to the discovery of darbepoetin alfa (Aranesp®), a novel erythropoiesis stimulating agent (ESA) currently approved for treatment of anemia in patients with chronic kidney disease and chemotherapy induced anemia.
Following the discovery and development of recombinant erythropoietin and the later development of darbepoetin, it became apparent that there were those who would choose to use ESAs improperly to enhance their performance in endurance sports. During the 2002 Winter games, Olympic Lab scientists ran multiple tests on samples and worked with Steve to confirm the detection of darbepoetin in several urine samples. He wrote letters to the International Olympic Committee verifying the findings. The three cross-country skiers from whom the samples had been taken were stripped of gold medals and suspended from competing for two years. When the three accused athletes appealed the rulings, He flew to Switzerland to testify in court against them, and all three appeals were denied. He has since then continued to support education and testing programs to discourage inappropriate use of ESAs and other medicines.
He recently retired from his Scientific Executive Director position at Amgen but has retained a consulting relationship where he has continued his anti-doping efforts. Steve received a BS degree in biological sciences in 1974 and a Ph.D in Molecular Biology and Biochemistry in 1978 from UC Irvine.
Dress code: Business Casual
- Check the company at www.amgen.com
- Wear your name badges
- Ask questions
Contact information: Kathy McNevin, email@example.com